Analysts Set Fresenius Medical Care AG (NYSE:FMS) Price Target at $24.00

Fresenius Medical Care AG (NYSE:FMS) has been assigned a consensus rating of “Hold” from the seven analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $24.00.

Separately, StockNews.com assumed coverage on Fresenius Medical Care in a research report on Saturday, May 4th. They set a “strong-buy” rating on the stock.

Institutional Investors Weigh In On Fresenius Medical Care

Large investors have recently modified their holdings of the business. Advisor Partners II LLC raised its stake in shares of Fresenius Medical Care by 16.3% in the third quarter. Advisor Partners II LLC now owns 10,836 shares of the company’s stock worth $233,000 after purchasing an additional 1,518 shares during the last quarter. Inspire Investing LLC purchased a new position in shares of Fresenius Medical Care during the 3rd quarter valued at about $600,000. First Trust Direct Indexing L.P. lifted its holdings in shares of Fresenius Medical Care by 6.6% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 23,888 shares of the company’s stock valued at $515,000 after buying an additional 1,482 shares during the period. Signaturefd LLC grew its holdings in Fresenius Medical Care by 7.3% during the third quarter. Signaturefd LLC now owns 8,601 shares of the company’s stock worth $185,000 after acquiring an additional 584 shares during the period. Finally, Syon Capital LLC acquired a new position in Fresenius Medical Care in the third quarter valued at approximately $384,000. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Up 2.9 %

Shares of NYSE:FMS opened at $20.69 on Friday. Fresenius Medical Care has a 52-week low of $16.37 and a 52-week high of $27.72. The stock has a market cap of $12.14 billion, a P/E ratio of 22.49, a price-to-earnings-growth ratio of 1.16 and a beta of 0.95. The business’s 50 day moving average is $19.66 and its 200 day moving average is $19.65. The company has a quick ratio of 1.07, a current ratio of 1.42 and a debt-to-equity ratio of 0.47.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings data on Tuesday, February 20th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.11. Fresenius Medical Care had a return on equity of 4.99% and a net margin of 2.56%. The company had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.32 billion. Sell-side analysts predict that Fresenius Medical Care will post 1.49 EPS for the current year.

Fresenius Medical Care Cuts Dividend

The firm also recently declared an annual dividend, which will be paid on Monday, June 3rd. Shareholders of record on Monday, May 20th will be paid a $0.437 dividend. This represents a yield of 2.35%. The ex-dividend date of this dividend is Friday, May 17th. Fresenius Medical Care’s dividend payout ratio (DPR) is presently 46.74%.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.